from quality-of-life impairment, had ever consulted a physician, or required any treatments. In our opinion, further studies are needed to determine whether these 35 individuals truly correspond to pathological cases of acquired vibratory angioedema or rather exacerbated physiological responses to vibratory stimuli.

We agree with our colleagues that vibratory urticaria/angioedema should be correctly diagnosed, and we encourage others to share their experience in the published literature.

Maria Antonia Pastor-Nieto, MD
dMaria Elena Gatica-Ortega, MD
dLaura Vergara-de-la-Campa, MD
da Maria Giménez-Arnau, MD

1. Dermatology Department, University Hospital of Guadalajara, Guadalajara, Spain
2. Medicine and Medical Specialties Department, Faculty of Medicine and Health Sciences, University of Alcalá de Henares, Alcalá de Henares, Spain
3. Dermatology Department, Hospital Complex of Toledo, Toledo, Spain
4. Dermatology Department, Hospital del Mar IMIM, Universitat Autònoma, Barcelona, Spain.

No funding was received for this work.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

No funding was received for this work.

To The Editor:

We thank Dr. Pastor-Nieto for her interest in our recent publication of a systematic review of vibratory angioedema (VA) and proposal for its classification.1,2

In line with Dr. Pastor-Nieto’s suggestion to subclassify hereditary VA (HVA), we distinguish 2 HVA subgroups, that is, due to a mutation in adhesion G protein-coupled receptor E2 (ADGRE2; 24 cases) and due to unknown cause (4 cases not investigated for their underlying genetic mutation).3 ADGRE2-mediated HVA manifests with transient whealing (<1 hour),5,6 whereas HVA patients with unknown mutation have angioedema (hours to days).7 This may suggest that HVA in the latter patients is not due to ADGRE2, but does not exclude this. Further analyses of these and other HVA patients are needed to understand if the described ADGRE2 mutation is the only mutation that drives HVA. Until further information becomes available, we prefer to subclassify HVA as “due to ADGRE2 mutation” and “due to unknown cause.”

Acquired vibratory angioedema (AVA) can present with wheals, angioedema, or both, and disease activity ranges from mild to severe. AVA may, therefore, be subclassified by clinical phenotypes or by disease activity. Dr. Pastor-Nieto’s suggestion to subclassify AVA as primary and secondary, that is, AVA without and with an underlying cause, respectively, is interesting. Two of 55 AVA patients (3.6%) had a potential cause, that is, a Candida glabrata urinary tract infection8 and a Hymenoptera sting.2,7 Secondary cases of cold urticaria, a form of chronic inducible urticaria (ClU) like AVA, have been described, anecdotally, but this is not very helpful.8 The pathogenesis and cause(s) of ClUs

References

including AVA are currently unclear. Insect stings, infections, and other events or conditions that occur at the time of onset of CIndU or shortly before may be coincidental or may have triggered the development of CIndU without being responsible for its persistence. Even in cases where CIndU patients were treated for a “cause,” for example, a chronic infection, and experienced remission of their CIndU, this does not prove a causal relationship. CIndU remission may have occurred spontaneously, or the anti-infective treatment may have cured the CIndU by eradication of another infection or by off-target effects. Most suspected causes of CIndU, insect stings for example, cannot be eradicated and are, therefore, not of therapeutic relevance. A search for underlying mechanisms, in the management of patients with CIndU including AVA, does not usually benefit patients, but rather raises false hopes of a possible cure, incurs costs, may lead to ineffective treatment, and can delay appropriate treatment. We suggest to consider all cases of AVA, until we know the cause(s) of this disease, as primary.

AVA is a rare form of CIndU. The global chronic urticaria registry (CURE, www.urticaria-registry.com) of the GA2LEN network of urticaria centers of reference and excellence (UCAREs, www.ga2len-ucare.com) can help to collect more cases of VA and to increase our knowledge of VA.3,10 Identifying and characterizing the underlying causes and pathogenesis of CIndUs including AVA is of the highest priority and may allow for the development of novel and better treatments including curative treatments. When we have more data and a clear understanding of the etiopathogenesis of VA, revising its classification may be possible and helpful.

To the Editor:

Yeoh et al.1 describe a challenging case of invasive conidiobolomycosis managed with mepolizumab. However, the index case described by the authors appears to be an allergic inflammatory response to Conidiobolus. A Th2 response to the fungi (elevated eosinophils and total IgE), histopathology showing eosinophil-rich inflammation, a prolonged course lasting for nearly a year, and a good response to glucocorticoids and mepolizumab suggest an allergic inflammation. Also, a lack of progression of invasive infection despite high-dose glucocorticoids and mepolizumab therapy implies otherwise.2 The clinical and radiologic presentation described by the authors probably represents bronchocentric granulomatosis. However, the authors have not presented computed tomography images.

The authors rightly cite the example of allergic bronchopulmonary aspergillosis,3 wherein such presentations are previously described. Aspergillus fumigatus is the most extensively studied of the environmental fungi pathogenic to humans. A spectrum of manifestations can occur in humans (saprolegnious colonization, allergic response, and invasive) depending on the fungal burden and the host immune response. A similar allergic reaction to fungi other than A. fumigatus has been well described.4 Although the clinical presentation and available investigations suggest an allergic response to Conidiobolus, the performance of skin testing or demonstration of IgE against the culture filtrate antigens of the Conidiobolus isolate would help in confirming the allergic nature.5

The distinction between allergic and invasive forms is important because high doses of glucocorticoids and immunomodulatory treatments may be harmful in the invasive variety of thoracic or disseminated conidiobolomycosis.

Thoracic conidiobolomycosis: Invasive or allergic?

Kanokvalai Kulthanan, MDa
Patompong Ungprasert, MD, MSd
Sompot Tacepmuch, MD, PhDc
Chuda Rujitharanawong, MDa
Rungsima Kiratiwongwan, MDa
Kanyalak Munprom, MDc
Dorothea Terhorst-Molawi, MDf
Marcus Maurer, MDf

aDepartment of Dermatology, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand
bClinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
cDepartment of Physiology, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand
dDermatological Allergology, Allergic-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany (corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany)

No funding was received for this work.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication February 6, 2021; accepted for publication February 9, 2021.

Corresponding author: Marcus Maurer, MD, Dermatological Allergology, Allergic-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. E-mail: Marcus.Maurer@charite.de.

REFERENCES


https://doi.org/10.1016/j.jaip.2021.02.037